Henry Schein (HSIC) Expected to Announce Earnings on Tuesday

Henry Schein (NASDAQ:HSIC) is projected to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Henry Schein to announce earnings of $1.22 per share and revenue of $3.3734 billion for the quarter. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the prior year, the business earned $1.15 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts expect Henry Schein to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $84.61 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $9.64 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.65 and a beta of 0.81. The firm’s 50 day moving average price is $81.22 and its 200-day moving average price is $78.08. Henry Schein has a twelve month low of $61.94 and a twelve month high of $89.34.

Insider Activity

In other news, Director William K. Daniel bought 10,000 shares of Henry Schein stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Henry Schein

A number of hedge funds have recently modified their holdings of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein during the 2nd quarter valued at $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the second quarter valued at about $27,000. Federated Hermes Inc. purchased a new position in shares of Henry Schein in the fourth quarter valued at about $32,000. Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein during the fourth quarter worth about $37,000. Finally, Palisade Asset Management LLC bought a new stake in Henry Schein during the 3rd quarter valued at approximately $100,000. 96.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on HSIC shares. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a report on Wednesday, May 6th. BMO Capital Markets assumed coverage on shares of Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price target on the stock. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Thursday, June 11th. Morgan Stanley reissued an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Finally, Citigroup began coverage on Henry Schein in a research note on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $88.62.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.